Vertex Pharmaceuticals (NASDAQ: VRTX)
$484.98
(-1.6%)
-$7.72
Price as of March 31, 2025, 3:58 p.m. ET
VRTX
Key Data Points
Current Price
$484.98
Daily Change
(-1.6%) -$7.72
Day's Range
$472.01 - $487.13
Previous Close
$484.82
Open
$487.13
Beta
0.63
Volume
2,231,875
Average Volume
1,470,416
Sector
Market Cap
$124B
Market Cap / Employee
$20M
52wk Range
$377.85 - $519.88
Revenue
$11B
Gross Margin
86.07%
Dividend Yield
N/A
EPS
-$2.20
CAPs Rating
-
Industry
Biotechnology
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Vertex Pharmaceuticals Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Vertex Pharmaceuticals Company Info
Vertex is in the business of discovering, developing, and commercializing small-molecule drugs for the treatment of serious genetic diseases including cystic fibrosis.
News & Analysis
The Fool has written over 800 articles on Vertex Pharmaceuticals.
Featured Article
3 Unstoppable Stocks You Can Buy Now Without Any Hesitation
Keith Speights, David Jagielski, and Prosper Junior Bakiny | Mar 17, 2025
Featured Article
Where Will Vertex Pharmaceuticals Be in 10 Years?
Adria Cimino | Mar 11, 2025
If I Could Buy Only 1 Growth Stock, This Would Be It
Prosper Junior Bakiny | Mar 8, 2025
The Ultimate Healthcare Stock to Buy With $500 Right Now
Keith Speights | Feb 14, 2025
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
David Jagielski | Feb 14, 2025
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
Prosper Junior Bakiny | Feb 13, 2025
Vertex: Strong Sales, Stronger Pipeline
Matt Frankel | Feb 11, 2025
Vertex's Revenue Surges but EPS Slips
JesterAI | Feb 10, 2025
The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Podcast Episodes

Alleged Industrial Espionage Makes an Interesting Story
We also chat about Vertex Pharmaceuticals and its role at the center of cystic fibrosis treatment.
Motley Fool Staff, Bill Mann, Deidre Woollard, Kirsten Guerra, and Ricky Mulvey | Jun 21, 2023

3 Biotech Companies Analyzed
We examine three biotech companies' past performances and future outlooks.
Shannon Jones | Feb 6, 2020

Is Amarin's Fish Oil Pill on Track to Become a Blockbuster?
Plus, how gene-editing company CRISPR Therapeutics just took a big step forward.
Todd Campbell | Nov 22, 2019
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.